Unlocking the Power of AI in Drug Discovery

Table of Contents

1. Introduction
2. The State of the World Today
3. The Importance of Optimism
4. The Mission of BenevolentAI
5. The Challenge of Rare Diseases
6. The Cost of Developing New Drugs
7. The Efficacy of Top-Selling Drugs
8. The Impact of Chronic Diseases
9. The Complexity of Human Biology
10. The Power of AI in Drug Discovery
11. The Benevolent Knowledge Graph
12. The Automated Platform for Drug Discovery
13. The Importance of Collaboration
14. The Benevolent Approach
15. Conclusion

The Power of AI in Drug Discovery

The world is facing a major challenge when it comes to the development of new treatments for diseases. There are currently over 9,000 diseases that have no treatment, and over 300 million people suffering from rare diseases for which no treatment will ever be developed. This is due to the current economic and development models, which are not conducive to the development of new treatments.

Despite the fact that many industries have been transformed by technology, it still costs 2.5 billion dollars to take a new drug from discovery to FDA approval, and it can take 10 to 15 years before it is given to patients. Furthermore, the efficacy of the top-selling drugs is only 30 to 50 percent, meaning that they do not work for the patients they are prescribed for.

Chronic diseases such as Alzheimer's and diabetes are already placing an unprecedented burden on families, with roughly eight out of ten elderly people suffering from these diseases. Many of us have experienced the agonizing experience of watching someone we love suffer from a disease that has no treatment.

The complexity of human biology is a major factor in the challenge of developing new treatments. The human body represents a living breathing big data system with over 37 trillion cells. In addition, there are more than 10,000 scientific papers published every single day in the biomedical domain alone, making it impossible for even the most learned scientists and research teams to keep up.

This is where the power of AI comes in. At BenevolentAI, we have developed the world's leading AI-powered drug discovery and development platform to accelerate the Journey from data to medicine. Our platform helps research teams and scientists navigate the Scale of data that has previously been impossible to process and comprehend. Our inference algorithms and models help uncover new insights and knowledge to discover and develop more effective medicines faster than ever before.

We started with an audacious goal to Create the world's largest biomedical knowledge base, and that's precisely what we've done. Five years on, the Benevolent Knowledge Graph contains over a billion contextualized machine-curated relationships, more than a third of which are proprietary developed to guide the process of validating hypotheses and experiments. Together, these biological facts represent all of this thought that is known to be true about a disease.

Our algorithms analyze vast corpus of data, reason across it, and provide scientists with research capabilities beyond human Insight. We ingest millions of chemical structures and use state-of-the-art AI to create the largest drug light chemical space to facilitate the design of the right molecule for the right patient. We have built a suite of tools that make this output interoperable and actionable by scientists.

The result is an automated platform that powers target ID to define the underlying cause of disease, molecular design to develop the most effective medicine to treat that disease, and patient stratification to understand how individual patients will respond to that treatment.

At BenevolentAI, we recognize that no business can revolutionize a sector of the scale of drug development all on its own. To change the status quo of the way medicines are discovered and developed, and to substantially reduce costs and ensure treatments are more effective for patients, we need a dramatically different approach.

In addition to our commercial collaborations, we believe we must be benevolent ourselves. This means that We Are not going to use the technology to harvest and ring-fence information, but to plan. We plan to open our platform and make it available to academics, researchers, and scientists, not for the benefit of a few, but to enrich us all.

BenevolentAI is the most remarkable company I've ever had the privilege to be part of. Of all the ventures that I have been involved with since I began my career 30 years ago in Silicon Valley, this is the most exciting and ambitious. But by far, it's also the most principled. As AI empowers the next Wave of technological advancement, we need moral leadership and strong conviction to ensure that what we develop benefits everyone.

At BenevolentAI, we have 200 biologists, chemists, engineers, informaticians, and data scientists working in radical cross-functional squads to push the boundaries of AI to unlock the power of decades of research to understand the underlying cause of disease and develop new treatments for the millions of patients who need them. We do it to disrupt and remake the way drugs are discovered and developed. We do it to benefit humanity. And we do it because it matters.

Highlights

• BenevolentAI has developed the world's leading AI-powered drug discovery and development platform to accelerate the journey from data to medicine.
• The Benevolent Knowledge Graph contains over a billion contextualized machine-curated relationships, more than a third of which are proprietary developed to guide the process of validating hypotheses and experiments.
• Our algorithms analyze vast corpus of data, reason across it, and provide scientists with research capabilities beyond human insight.
• We ingest millions of chemical structures and use state-of-the-art AI to create the largest drug light chemical space to facilitate the design of the right molecule for the right patient.
• Our automated platform powers target ID to define the underlying cause of disease, molecular design to develop the most effective medicine to treat that disease, and patient stratification to understand how individual patients will respond to that treatment.
• We plan to open our platform and make it available to academics, researchers, and scientists, not for the benefit of a few, but to enrich us all.

FAQ

Q: What is BenevolentAI? A: BenevolentAI is a company that has developed the world's leading AI-powered drug discovery and development platform to accelerate the journey from data to medicine.

Q: What is the Benevolent Knowledge Graph? A: The Benevolent Knowledge Graph contains over a billion contextualized machine-curated relationships, more than a third of which are proprietary developed to guide the process of validating hypotheses and experiments.

Q: How does BenevolentAI use AI in drug discovery? A: BenevolentAI uses AI to analyze vast corpus of data, reason across it, and provide scientists with research capabilities beyond human insight. We ingest millions of chemical structures and use state-of-the-art AI to create the largest drug light chemical space to facilitate the design of the right molecule for the right patient.

Q: What is the mission of BenevolentAI? A: The mission of BenevolentAI is to disrupt and remake the way drugs are discovered and developed so that no disease goes untreated.

Q: How does BenevolentAI plan to make its platform available to academics, researchers, and scientists? A: BenevolentAI plans to open its platform and make it available to academics, researchers, and scientists, not for the benefit of a few, but to enrich us all.